The short version
- Why people research itLibido, hormonal signaling and reproductive / sexual function.
- What the evidence isApproved for hormone-receptor-positive breast cancer with substantial trial data, including the MA.17 and TEAM programs.
- What to watchBone pain or a low-impact fracture.
How Exemestane works
Steroidal ('suicidal') aromatase inhibitor — permanently disables aromatase, lowering estrogen without the rebound of non-steroidal AIs.
Aromatase is CYP19A1, a cytochrome P450 that performs three successive oxidations on the C19 methyl group of androstenedione or testosterone and ends by aromatizing the A ring — androstenedione becomes estrone, testosterone becomes estradiol. Anastrozole and letrozole are triazoles that sit in the heme pocket and coordinate the iron.
It is a steroid, and the enzyme mistakes it for its own substrate. Exemestane is 6-methylenandrosta-1,4-diene-3,17-dione — an androstenedione skeleton with a 6-methylene group bolted on. The label's own words are that it is an irreversible, steroidal aromatase inactivator that acts as a false substrate and produces suicide inhibition US Food and Drug Administration 2024.
- Oral
On the goal map: Aromatase & estrogen management (Testosterone & the male hormonal axis)
Research on Exemestane4 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
Approved for hormone-receptor-positive breast cancer with substantial trial data, including the MA.17 and TEAM programs.
Correlative data
Used similarly to anastrozole in a male hormonal context, less commonly. Reported experience is of a smoother, less crash-prone effect, which the mechanism supports.
How the mechanism reads
A steroidal, irreversible aromatase inhibitor — it binds the enzyme permanently, so recovery requires synthesizing new enzyme.
MechanisticThat predicts the two reported differences from anastrozole: no estrogen rebound on cessation.
Mechanistic
Sources
- Paridaens R, Thomas J, Wildiers J, Vermeiren P, Lobelle JP, di Salle E, Ornati G, Zurlo MG, Polli A, Lanzalone S, de Belder K. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.. Anticancer Drugs 1998 · PMID 9823425
- Ariazi EA, Leitão A, Oprea TI. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen.. Mol Cancer Ther 2007 · PMID 17989318
- Goss PE, Ingle JN, Alés-Martínez JE. Exemestane for breast-cancer prevention in postmenopausal women.. N Engl J Med 2011 · PMID 21639806
- Cheung AM, Tile L, Cardew S. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.. Lancet Oncol 2012 · PMID 22318095
- Peterson A, Xia Z, Chen G. In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane.. Pharmacol Res Perspect 2017 · PMID 28603633
- Bertelsen BE, Almås B, Fjermeros K. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.. Breast Cancer Res Treat 2024 · PMID 38649619
- Lønning PE, Geisler J, Krag LE. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.. J Clin Oncol 2005 · PMID 15983390
- US Food and Drug Administration. AROMASIN (exemestane) tablets, for oral use - full prescribing information.. FDA approved labeling, revision 2024
Exemestane safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Osteoporosis or low bone density, because it cost bone in healthy postmenopausal women.
- Premenopausal women or pregnancy.
- Liver disease, because exemestane is cleared through CYP3A4.
- Men whose estradiol is already low.
- Under 18, where estrogen suppression would stunt bone growth.
What’s expected
- Estradiol drops and, in men, testosterone rises.
- Joint aches and hot flushes.
- Its androgenic 17-hydroxy metabolite may cause mild acne or hair changes.
Watch for
- Bone pain or a low-impact fracture.
- Severe joint stiffness.
- Flat mood or loss of drive.
Labs that tell you it’s working
- Estradiol: use the sensitive assay to see the actual suppression.
- Vitamin D (25-Hydroxy): bone protection needs adequate vitamin D when estrogen falls.
- Lipid Panel: estrogen loss shifts HDL and LDL.
- Total & Free Testosterone: rises as aromatase is permanently disabled.
Steroidal irreversible aromatase inactivator: permanent enzyme loss lowers estrogen; bone cost was measured in healthy women, and its metabolite is androgenic. PMID 22318095 PMID 17989318 PMID 21639806
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Exemestane FAQ4 common questions
- Is Exemestane approved for human use?
- No. Exemestane is a research compound.
- What is Exemestane researched for?
- Libido, hormonal signaling and reproductive / sexual function.
- Which labs show whether it's doing anything?
- Estradiol; Vitamin D; Lipid Panel; Total & Free Testosterone: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Exemestane: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



